Literature DB >> 8957010

Proteolytic activity in amyotrophic lateral sclerosis IgG preparations.

O Nyormoi1.   

Abstract

Sporadic amyotrophic lateral sclerosis is a motor neuron disease of unknown origin. Autoimmunity against voltage-gated calcium channels is one mechanism hypothesized to be the cause of the disease. In support of this hypothesis, it was previously reported that amyotrophic lateral sclerosis IgG specifically blocked the binding of 8B7 monoclonal antibody to the alpha1 subunit of voltage-gated calcium channels, suggesting overlapping epitopes of the two antibodies. It is, however, possible that the 8B7 epitope was destroyed by proteases. Data presented here show that the blocking of 8B7 binding to the alpha1 subunit by diethylaminoethyl cellulose (DEAE)-purified amyotrophic lateral sclerosis IgG was not observed with Fab fragments of amyotrophic lateral sclerosis IgG. The blocking was prevented by serine protease inhibitors. Moreover, it was reproduced by plasminogen and urokinase. These observations suggest that raised proteolytic activity in amyotrophic lateral sclerosis IgG preparations may be responsible for the blockade of 8B7 monoclonal antibody demonstrated previously. They also indicate the need to be particularly cautious when interpreting the results of incubation in amyotrophic lateral sclerosis sera or IgG preparations. Furthermore, they suggest that proteases may be partly responsible for some of the effects previously described for amyotrophic lateral sclerosis IgG. However, the proteolytic activity needs to be better defined and its possible role in amyotrophic lateral sclerosis investigated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957010     DOI: 10.1002/ana.410400505

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  5 in total

1.  Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells.

Authors:  O Nyormoi; Z Wang; D Doan; M Ruiz; D McConkey; M Bar-Eli
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 2.  Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.

Authors:  Barry W Festoff; Zhiming Suo; Bruce A Citron
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  Calcium signaling pathways mediating synaptic potentiation triggered by amyotrophic lateral sclerosis IgG in motor nerve terminals.

Authors:  Mario R Pagani; Ricardo C Reisin; Osvaldo D Uchitel
Journal:  J Neurosci       Date:  2006-03-08       Impact factor: 6.167

4.  Immunoglobulins from motoneurone disease patients enhance glutamate release from rat hippocampal neurones in culture.

Authors:  P R Andjus; Z Stevic-Marinkovic; E Cherubini
Journal:  J Physiol       Date:  1997-10-01       Impact factor: 5.182

5.  Autoimmunity in amyotrophic lateral sclerosis: past and present.

Authors:  Mario Rafael Pagani; Laura Elisabeth Gonzalez; Osvaldo Daniel Uchitel
Journal:  Neurol Res Int       Date:  2011-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.